Phase 1 Study of Pandemic H1 DNA Vaccine in Healthy Adults
Authors:
Open Access
- 17 April 2015
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 10 (4) , e0123969
Abstract
A novel, swine-origin influenza A (H1N1) virus was detected worldwide in April 2009, and the World Health Organization (WHO) declared a global pandemic that June. DNA vaccine priming improves responses to inactivated influenza vaccines. We describe the rapid production and clinical evaluation of a DNA vaccine encoding the hemagglutinin protein of the 2009 pandemic A/California/04/2009(H1N1) influenza virus, accomplished nearly two months faster than production of A/California/07/2009(H1N1) licensed monovalent inactivated vaccine (MIV). 20 subjects received three H1 DNA vaccinations (4 mg intramuscularly with Biojector) at 4-week intervals. Eighteen subjects received an optional boost when the licensed H1N1 MIV became available. The interval between the third H1 DNA injection and MIV boost was 3–17 weeks. Vaccine safety was assessed by clinical observation, laboratory parameters, and 7-day solicited reactogenicity. Antibody responses were assessed by ELISA, HAI and neutralization assays, and T cell responses by ELISpot and flow cytometry. Vaccinations were safe and well-tolerated. As evaluated by HAI, 6/20 developed positive responses at 4 weeks after third DNA injection and 13/18 at 4 weeks after MIV boost. Similar results were detected in neutralization assays. T cell responses were detected after DNA and MIV. The antibody responses were significantly amplified by the MIV boost, however, the boost did not increased T cell responses induced by DNA vaccine. H1 DNA vaccine was produced quickly, was well-tolerated, and had modest immunogenicity as a single agent. Other HA DNA prime-MIV boost regimens utilizing one DNA prime vaccination and longer boost intervals have shown significant immunogenicity. Rapid and large-scale production of HA DNA vaccines has the potential to contribute to an efficient response against future influenza pandemics. Clinicaltrials.gov NCT00973895Keywords
This publication has 32 references indexed in Scilit:
- DNA Vaccine Delivered by a Needle-Free Injection Device Improves Potency of Priming for Antibody and CD8+ T-Cell Responses after rAd5 Boost in a Randomized Clinical TrialPLOS ONE, 2013
- Trial of 2009 Influenza A (H1N1) Monovalent MF59-Adjuvanted VaccineNew England Journal of Medicine, 2009
- Response to a Monovalent 2009 Influenza A (H1N1) VaccineNew England Journal of Medicine, 2009
- Cross-Reactive Antibody Responses to the 2009 Pandemic H1N1 Influenza VirusNew England Journal of Medicine, 2009
- Emergence of a Novel Swine-Origin Influenza A (H1N1) Virus in HumansNew England Journal of Medicine, 2009
- A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trialVaccine, 2008
- A West Nile Virus DNA Vaccine Induces Neutralizing Antibody in Healthy Adults during a Phase 1 Clinical TrialThe Journal of Infectious Diseases, 2007
- Phase 1 Safety and Immunogenicity Evaluation of a Multiclade HIV‐1 Candidate Vaccine Delivered by a Replication‐Defective Recombinant Adenovirus VectorThe Journal of Infectious Diseases, 2006
- Protective immunity to lethal challenge of the 1918 pandemic influenza virus by vaccinationProceedings of the National Academy of Sciences, 2006
- A DNA vaccine induces SARS coronavirus neutralization and protective immunity in miceNature, 2004